Sympathetic activation in heart failure: A target of therapeutic approaches

被引:2
|
作者
P. Schnabel
M. Böhm
机构
[1] Klinik III für Innere Medizin der Universität zu Köln,
[2] Joseph-Stelzmann-Str. 9,undefined
[3] D-50924 Köln,undefined
[4] Germany,undefined
来源
Zeitschrift für Kardiologie | 1999年 / 88卷 / Suppl 3期
关键词
Key words Heart failure – neuroendocrine activation – sympathetic nervous system – signal transduction;
D O I
10.1007/s003920050575
中图分类号
学科分类号
摘要
In heart failure, decreased cardiac output leads to a number of adaptive mechanisms. Among these, neuroendocrine activation including activation of the renin-angiotensin-aldosterone system, augmentation of vasopressin and endothelin release, and activation of the sympathetic nervous system occur. The increase of adrenergic drive is characterized by decreased baroreceptor sensitivity, increased plasma norepinephrine levels and cardiac norepinephrine spillover, and desensitization of postsynaptic β-adrenergic signal transduction. While increased sympathetic drive initially helps to maintain contractile performance of the damaged heart, the above changes chronically result in catecholamine refractoriness and are associated with a poor prognosis.
引用
收藏
页码:S005 / S011
相关论文
共 50 条
  • [41] Heart failure: an underestimated therapeutic target in diabetes
    Marx, Nikolaus
    CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2018, 7 (01): : 10 - 12
  • [42] Is the Brain the Alternative Therapeutic Target for Heart Failure?
    Watanabe, Tetsu
    CIRCULATION JOURNAL, 2016, 80 (08) : 1702 - 1703
  • [43] Vasopressin: A therapeutic target in congestive heart failure?
    Goldsmith, SR
    JOURNAL OF CARDIAC FAILURE, 1999, 5 (04) : 347 - 356
  • [44] Hyperuricemia is a new therapeutic target of heart failure
    Yoshiharu, K
    Kasuhide, O
    Yoko, T
    Masahiko, K
    Shuichi, O
    Toru, K
    Osamu, I
    Ichiro, H
    Chiaki, S
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (05) : S192 - S192
  • [45] The interstitial compartment as a therapeutic target in heart failure
    Aronson, Doron
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [46] Mitochondrial function as a therapeutic target in heart failure
    David A. Brown
    Justin B. Perry
    Mitchell E. Allen
    Hani N. Sabbah
    Brian L. Stauffer
    Saame Raza Shaikh
    John G. F. Cleland
    Wilson S. Colucci
    Javed Butler
    Adriaan A. Voors
    Stefan D. Anker
    Bertram Pitt
    Burkert Pieske
    Gerasimos Filippatos
    Stephen J. Greene
    Mihai Gheorghiade
    Nature Reviews Cardiology, 2017, 14 : 238 - 250
  • [47] Myocardial infarction, heart failure and sympathetic nervous system activity: new pharmacological approaches that affect neurohumoral activation
    Ciarka, Agnieszka
    van de Borne, Philippe
    Pathak, Atul
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (09) : 1315 - 1330
  • [48] Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers
    Grassi, Guido
    Bolla, Gianbattista
    Quarti-Trevano, Fosca
    Arenare, Francesca
    Brambilla, Gianmaria
    Mancia, Giuseppe
    EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (12) : 1186 - 1191
  • [49] Paradoxical Muscle Sympathetic Reflex Activation in Human Heart Failure
    Millar, Philip J.
    Murai, Hisayoshi
    Floras, John S.
    CIRCULATION, 2015, 131 (05) : 459 - 468
  • [50] INFLAMMATION AND SYMPATHETIC ACTIVATION IN HEART FAILURE: CORRELATION WITH EXERCISE PARAMETERS
    Mesquita, Claudio Tinoco
    Messias, Leandro
    Nobrega, Antonio
    Azevedo, Jader
    Felix, Renata
    Miranda, Sandra
    Marostica, Elisabeth
    Mesquita, Evandro
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1165 - E1165